- Home
- CLBR vs ACIU Comparison
CLBR vs ACIU Comparison
Compare CLBR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLBR
- ACIU
- Stock Information
- Founded
- CLBR 2023
- ACIU 2003
- Country
- CLBR United States
- ACIU Switzerland
- Employees
- CLBR N/A
- ACIU N/A
- Industry
- CLBR
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- CLBR
- ACIU Health Care
- Exchange
- CLBR Nasdaq
- ACIU Nasdaq
- Market Cap
- CLBR 226.0M
- ACIU 247.4M
- IPO Year
- CLBR 2023
- ACIU 2016
- Fundamental
- Price
- CLBR $10.91
- ACIU $1.80
- Analyst Decision
- CLBR
- ACIU Strong Buy
- Analyst Count
- CLBR 0
- ACIU 2
- Target Price
- CLBR N/A
- ACIU $12.00
- AVG Volume (30 Days)
- CLBR 178.6K
- ACIU 190.8K
- Earning Date
- CLBR 01-01-0001
- ACIU 03-13-2025
- Dividend Yield
- CLBR N/A
- ACIU N/A
- EPS Growth
- CLBR N/A
- ACIU N/A
- EPS
- CLBR 0.27
- ACIU N/A
- Revenue
- CLBR N/A
- ACIU $30,136,397.00
- Revenue This Year
- CLBR N/A
- ACIU $120.91
- Revenue Next Year
- CLBR N/A
- ACIU $13.82
- P/E Ratio
- CLBR $39.30
- ACIU N/A
- Revenue Growth
- CLBR N/A
- ACIU 84.51
- 52 Week Low
- CLBR $10.15
- ACIU $1.77
- 52 Week High
- CLBR $12.28
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- CLBR 67.12
- ACIU 20.92
- Support Level
- CLBR $10.60
- ACIU $1.95
- Resistance Level
- CLBR $10.74
- ACIU $2.05
- Average True Range (ATR)
- CLBR 0.09
- ACIU 0.12
- MACD
- CLBR 0.03
- ACIU -0.03
- Stochastic Oscillator
- CLBR 89.47
- ACIU 4.10
About CLBR Colombier Acquisition Corp. II
Colombier Acquisition Corp II is a blank check company.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.